Not automatically. FDA’s April 1, 2026 clarification specifically explains that a semaglutide–B12 combination may still be considered essentially a copy under the circumstances it describes. (fda.gov)
Similarly, FDA’s 503A guidance addresses minor strength changes and easily substitutable strengths; a cosmetic difference is not a general exemption. (fda.gov)
Treat these supplier statements as requests for evidence, not conclusions:
- The formula is personalized.
- The dose is different from the branded pen.
- B12 makes it a different medicine.
- Every patient receives an individual prescription.
For each, request the exact formulation, applicable legal test and independent prescriber documentation. An ingredient addition also warrants clinical review of its purpose—not just a commercial explanation of why it enables continued selling.
Decision rule: unresolved copying questions remain a procurement gate. They should not receive a low risk score that can be offset by a large discount.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- fda.gov · Source 2 ↗https://www.fda.gov/files/drugs/published/Compounded-Drug-Products-That-Are-Essentially-Copies-of-a-Commercially-Available-Drug-Product-Under-Section-503A-of-the-Federal-Food--Drug--and-Cosmetic-Act-Guidance-for-Industry.pdf